BeiGene, a venture fund established in 2010, operates in Changping, China, with a focus on Series A and Series B investments in BioTech, Healthcare, Life Science, and Medical Device sectors. The fund, led by Partner Karyn Parra, has invested in 4 companies, including Shoreline Biosciences, and has had 1 successful exit. BeiGene is known for its dedication to advancing life sciences and biotechnology. For more information, visit their website at www.beigene.com.